Ventyx Biosciences Announces $176.6 Million Private Placement of Common Stock
September 19, 2022 08:00 ET
|
Ventyx Biosciences, Inc.
ENCINITAS, Calif., Sept. 19, 2022 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that...
Ventyx Biosciences to Participate in Two Upcoming Investor Conferences
August 29, 2022 16:05 ET
|
Ventyx Biosciences, Inc.
ENCINITAS, Calif., Aug. 29, 2022 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX), (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that...
Ventyx Biosciences Reports Second Quarter 2022 Financial Results and Highlights Recent Corporate Progress
August 15, 2022 16:05 ET
|
Ventyx Biosciences, Inc.
VTX958, our allosteric TYK2 inhibitor, demonstrated an excellent safety profile and class-leading target coverage in Phase 1 trial Cash, cash equivalents and marketable securities of $258.4 million...
Ventyx Biosciences Announces Positive Topline Phase 1 Data for Its Selective Allosteric TYK2 Inhibitor VTX958
August 15, 2022 16:01 ET
|
Ventyx Biosciences, Inc.
VTX958 was well-tolerated across all SAD and MAD cohorts with an excellent safety profile Class-leading target coverage, with TYK2 IC50 and IC90 coverage up to 24 hours Robust dose-dependent...
Ventyx Biosciences to Report Topline Results from the Phase 1 trial of its TYK 2 Inhibitor VTX958 and Second Quarter 2022 Financial Results on August 15, 2022
August 11, 2022 16:05 ET
|
Ventyx Biosciences, Inc.
ENCINITAS, Calif., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX), (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that...
Ventyx Biosciences Announces Positive Topline Phase 1 Data for its Peripheral NLRP3 Inhibitor VTX2735
June 29, 2022 08:00 ET
|
Ventyx Biosciences, Inc.
Excellent safety, tolerability and pharmacokinetic profile Robust dose-dependent target engagement as measured by ex vivo IL-1β release assay Phase 2 trial planned in CAPS patients to efficiently...
Ventyx Biosciences to Participate in the Jefferies Healthcare Conference
June 01, 2022 08:00 ET
|
Ventyx Biosciences, Inc.
ENCINITAS, Calif., June 01, 2022 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX), (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that...
Ventyx Biosciences Reports First Quarter 2022 Financial Results and Highlights Recent Corporate Progress
May 12, 2022 16:01 ET
|
Ventyx Biosciences, Inc.
Topline Phase 1 data for our allosteric TYK2 inhibitor, VTX958, expected in early Q3 2022 Topline Phase 1 data for our selective NLRP3 inhibitor, VTX2735, expected in Q2 2022 Announced the...
Ventyx Biosciences Announces Appointment of William Sandborn, MD, as President and Chief Medical Officer
May 09, 2022 08:00 ET
|
Ventyx Biosciences, Inc.
ENCINITAS, Calif., May 09, 2022 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX), (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that...
Ventyx Biosciences to Report First Quarter 2022 Financial Results on May 12, 2022
May 05, 2022 16:05 ET
|
Ventyx Biosciences, Inc.
ENCINITAS, Calif., May 05, 2022 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX), (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that...